Wall Street brokerages forecast that Uniqure NV (NASDAQ:QURE) will report earnings of ($0.48) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Uniqure’s earnings, with the lowest EPS estimate coming in at ($1.18) and the highest estimate coming in at ($0.72). Uniqure reported earnings per share of ($0.83) during the same quarter last year, which would suggest a positive year-over-year growth rate of 42.2%. The company is expected to issue its next quarterly earnings report on Monday, August 3rd.
On average, analysts expect that Uniqure will report full-year earnings of ($0.03) per share for the current fiscal year, with EPS estimates ranging from ($3.19) to $7.26. For the next year, analysts anticipate that the firm will report earnings of ($0.99) per share, with EPS estimates ranging from ($3.80) to $1.53. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Uniqure.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.21. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $1.76 million. Uniqure had a negative return on equity of 45.23% and a negative net margin of 1,991.17%.
In related news, insider Robert Gut sold 26,875 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total transaction of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 9,376 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $56.87, for a total value of $533,213.12. Following the transaction, the chief executive officer now directly owns 327,918 shares of the company’s stock, valued at approximately $18,648,696.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,002 shares of company stock valued at $3,044,829. 2.66% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the business. RMR Wealth Builders bought a new stake in shares of Uniqure in the 4th quarter worth $89,000. Bamco Inc. NY grew its holdings in shares of Uniqure by 34.2% in the fourth quarter. Bamco Inc. NY now owns 1,570 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 400 shares during the period. Sowell Financial Services LLC grew its holdings in shares of Uniqure by 451.2% in the first quarter. Sowell Financial Services LLC now owns 1,874 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 1,534 shares during the period. Sofos Investments Inc. grew its holdings in shares of Uniqure by 18.9% in the fourth quarter. Sofos Investments Inc. now owns 1,939 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 308 shares during the period. Finally, Brinker Capital Inc. bought a new stake in shares of Uniqure in the fourth quarter worth $206,000. 78.65% of the stock is owned by institutional investors and hedge funds.
NASDAQ QURE opened at $45.73 on Friday. The business has a 50 day moving average price of $61.36 and a 200-day moving average price of $59.87. Uniqure has a 52 week low of $36.20 and a 52 week high of $77.46. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.89 and a current ratio of 12.89.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Article: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.